FAQs

Three things consistently differentiate this event:

• A focused audience of 70-100 oligonucleotide specialists rather than a broad RNA audience
• Deep technical discussions on delivery, chemistry, targeting and efficacy challenges
• Built-in networking formats designed to facilitate meaningful conversations and collaboration opportunities

The programme has been specifically developed to help attendees solve practical problems they are facing in development today.

Yes. This summit is designed for scientists already working in oligonucleotide therapeutics and is intentionally focused on technical detail, practical lessons learned, and emerging innovation. Sessions move beyond introductory content and into the real challenges facing programmes today.

The agenda is built around some of the industry's biggest scientific questions, including:

• Delivery beyond the liver
• Endosomal escape
• Conjugates, ligands and linker design
• Novel oligonucleotide chemistries
• Tissue-specific targeting
• AI-enabled delivery discovery
• Translation from preclinical development to the clinic
• Partnership and investment readiness

No. While manufacturability is discussed where relevant, this summit is primarily focused on innovation in oligonucleotide chemistry, delivery, targeting and therapeutic performance rather than manufacturing or analytical development challenges.

No. The summit takes a disease-agnostic approach, bringing together scientists working across CNS, neuromuscular, metabolic, oncology, rare disease and other therapeutic areas to share transferable lessons and innovations.